Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00060515
Status:
TERMINATED
Last Update Posted:
2005-08-05
First Post:
2003-05-07
Brief Title:
RG2133 235-Tri-O-Acetyluridine in Mitochondrial Disease
Sponsor:
Repligen Corporation
Organization:
Repligen Corporation
Study Overview
Official Title:
An Open-Label Dose-Escalation Phase I Study to Asses the Safety Tolerability Pharmacokinetics and Pharmacodynamics of RG2133 235-Tri-O-Acetyluridine in the Treatment of Inherited Mitochondrial Diseases
Status:
TERMINATED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None